


## Mal-PEG8-Phe-Lys-PAB-Exatecan TFA

**Cat. No.:** HY-148380A  
**Molecular Formula:** C<sub>75</sub>H<sub>93</sub>F<sub>4</sub>N<sub>9</sub>O<sub>22</sub>  
**Molecular Weight:** 1548.58  
**Target:** Drug-Linker Conjugates for ADC  
**Pathway:** Antibody-drug Conjugate/ADC Related  
**Storage:** -20°C, protect from light  
 \* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (64.58 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent		Mass		
	Concentration		1 mg	5 mg	10 mg
	1 mM		0.6458 mL	3.2288 mL	6.4575 mL
	5 mM		0.1292 mL	0.6458 mL	1.2915 mL
	10 mM		0.0646 mL	0.3229 mL	0.6458 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Mal-PEG8-Phe-Lys-PAB-Exatecan TFA is a agent-linker conjugate for ADC, composed of degradable linker Mal-PEG8-Phe-Lys-PAB and toxin molecule Exatecan (HY-13631)<sup>[1]</sup>.

### REFERENCES

[1]. Manel KRAIEM. Treatment of cancer. Patent WO2021151984A1.

[2]. Manel KRAIEM. Treatment of cancer. Patent WO2021151984A1.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA